| 1 |
NCT03494036 |
Recruiting
New |
Effect of Synbiotic on Immune Response, Gut Permeability and Microbiota in Patient With Connective Tissue Disease |
- Connective Tissue Diseases
|
- Dietary Supplement: Synbiotic
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
- Fakultas Kedokteran Universitas Indonesia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- FOXP3 regulatory T cell
- IL-17
- zonulin
- gut microbiota
|
46 |
Female |
18 Years to 60 Years (Adult) |
NCT03494036 |
804/UN2.F1/ETIK/2017 |
|
October 1, 2017 |
July 31, 2018 |
August 31, 2018 |
April 11, 2018 |
April 12, 2018 |
|
- Cipto Mangunkusumo Hospital
Jakarta, Indonesia
|
| 2 |
NCT02234388 |
Recruiting |
Undifferentiated Connective Tissue Disease Registry |
- Undifferentiated Connective Tissue Disease
|
|
Observational |
|
- Hospital for Special Surgery, New York
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in SF-36 Score
- Change in Fatigue Severity Scale Score
- Change in Beck Depression Inventory Score
- (and 5 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02234388 |
2014-311
Robin J. Sillau Fund |
UCTD Registry |
March 2012 |
January 2020 |
|
September 9, 2014 |
March 15, 2018 |
|
- Hospital for Special Surgery
New York, New York, United States
|
| 3 |
NCT02657356 |
Recruiting |
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST |
- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
|
- Drug: Placebo capsules
- Drug: Bardoxolone methyl capsules
|
Interventional |
Phase 3 |
- Reata Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in six-minute-walk distance (6MWD)
|
200 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02657356 |
RTA 402-C-1504 |
|
October 4, 2016 |
December 2018 |
December 2018 |
January 15, 2016 |
April 3, 2018 |
|
- Banner University Medical Center, Phoenix Advanced Lung Disease Institute
Phoenix, Arizona, United States - Arizona Pulmonary Specialists
Phoenix, Arizona, United States - Cedars Sinai Medical Center
Beverly Hills, California, United States - (and 106 more...)
|
| 4 |
NCT00076830 |
Recruiting |
Evaluation and Treatment of Patients With Connective Tissue Disease |
- Connective Tissue Disorders
|
|
Observational |
|
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
400 |
All |
up to 70 Years (Child, Adult, Senior) |
NCT00076830 |
040077
04-CH-0077 |
|
February 3, 2004 |
|
|
February 4, 2004 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 5 |
NCT02768259 |
Recruiting |
Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients |
- Connective Tissue Diseases
- Pulmonary Hypertension
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02768259 |
Cairo2000 |
|
June 2016 |
May 2017 |
May 2017 |
May 11, 2016 |
July 12, 2016 |
|
- Kasr Alaini School of Medicine
Cairo, Egypt
|
| 6 |
NCT00582881 |
Recruiting |
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus |
- Mixed Connective Tissue Disease (MCTD)
- Systemic Lupus Erythematosus (SLE)
|
|
Observational |
|
- University of Miami
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Data characterizing immune cell responses and corresponding clinical data
- Phenotype measurement to include disease activity, disease severity, and functional status
|
400 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT00582881 |
20030724
5R01AR043308-16
5R01AR043308-14 |
|
October 2007 |
July 2020 |
July 2020 |
December 28, 2007 |
August 8, 2017 |
|
- University of Miami Miller School of Medicine
Miami, Florida, United States
|
| 7 |
NCT01862926 |
Recruiting |
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD |
- Interstitial Lung Disease
- Scleroderma
- Idiopathic Inflammatory Myositis
- Mixed Connective Tissue Disease
|
- Drug: Rituximab
- Drug: Cyclophosphamide
|
Interventional |
Phase 2
Phase 3 |
- Royal Brompton & Harefield NHS Foundation Trust
- Imperial College London
- University of East Anglia
- University College London Hospitals
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Absolute change in FVC
- • Change from baseline in diffusing capacity for carbon monoxide (DLco)
- • Change from baseline in health related quality of life scores
- (and 3 more...)
|
116 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01862926 |
RBHIPF004
2012-003633-42 |
RECITAL |
November 2014 |
November 2019 |
November 2020 |
May 27, 2013 |
June 8, 2017 |
|
- Royal Brompton Hospital
London, United Kingdom
|
| 8 |
NCT03446339 |
Recruiting |
Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE) |
- Connective Tissue Diseases
- Systemic Sclerosis
- Systemic Lupus Erythematosus
|
|
Observational |
|
- The University of Hong Kong
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Prevalence of asymptomatic pulmonary hypertension in Chinese patients with connective tissue diseases
- Clinical predictor of Echocardiography for pulmonary hypertension in Chinese patients with connective tissue diseases
- Clinical predictor of BNP assay for pulmonary hypertension in Chinese patients with connective tissue diseases
|
1800 |
All |
18 Years and older (Adult, Senior) |
NCT03446339 |
PH_Screening_1.4.2017 ver.1 |
PAH |
August 3, 2017 |
August 2020 |
December 2020 |
February 26, 2018 |
February 26, 2018 |
|
- The University of Hong Kong
Hong Kong, China
|
| 9 |
NCT03307616 |
Recruiting |
Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma |
- Systemic Connective Tissue Disorders
|
- Drug: Nivolumab
- Drug: Ipilimumab
- Radiation: Radiation Therapy
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathologic Response
- Immunologic Response
- Change in Immune Infiltrate in Response to Neoadjuvant Nivolumab Monotherapy and Neoadjuvant Nivolumab and Ipilimumab Combination Therapy
- (and 4 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03307616 |
2017-0143 |
|
October 4, 2017 |
October 2021 |
October 2022 |
October 12, 2017 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 10 |
NCT00001978 |
Recruiting |
Determination of Kidney Function |
- Kidney Disease
- Proteinuria
- Autoimmune / Connective Tissue Diseases
|
|
Observational |
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
9999999 |
All |
7 Years and older (Child, Adult, Senior) |
NCT00001978 |
890152
89-DK-0152 |
|
August 24, 1989 |
|
|
January 21, 2000 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 11 |
NCT02794285 |
Recruiting |
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus |
- Active Systemic Lupus Erythematosus
|
- Biological: Anifrolumab
- Drug: Placebo
|
Interventional |
Phase 3 |
- AstraZeneca
- PRA Health Sciences
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To measure the long-term safety and tolerability of IV anifrolumab by measuring the rates of adverse events of special interest and serious adverse events
|
575 |
All |
Child, Adult, Senior |
NCT02794285 |
D3461C00009 |
TULIP SLE LTE |
June 30, 2016 |
November 30, 2021 |
November 30, 2021 |
June 9, 2016 |
April 12, 2018 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Covina, California, United States - Research Site
El Cajon, California, United States - (and 280 more...)
|
| 12 |
NCT03269630 |
Recruiting |
New Orleans Pulmonary Hypertension Biobank |
- Pulmonary Hypertension
- Systemic Sclerosis
- Mixed Connective Tissue Disease
- (and 2 more...)
|
- Other: No intervention. Biospecimen collection only
|
Observational |
|
- Louisiana State University Health Sciences Center in New Orleans
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Collection of biospecimens
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT03269630 |
LSU |
NO-PH Biobank |
December 29, 2017 |
October 2027 |
October 2027 |
September 1, 2017 |
January 16, 2018 |
|
- University Medical Center-New Orleans
New Orleans, Louisiana, United States
|
| 13 |
NCT02298777 |
Recruiting |
Metabolomic Analysis of Systemic Sclerosis |
- Scleroderma (Limited and Diffuse)
- Undifferentiated Connective Tissue Disease
- Raynaud Disease
- (and 2 more...)
|
- Procedure: - Skin biopsy - Urine sample - Blood sample
|
Observational |
|
- University Hospital, Strasbourg, France
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- change of metabolomics profiles between SSc beginners (<3 years) and SSc established forms (> 3 years) at baseline inclusion.
- Study and comparison of discriminating metabolomics profiles for prognosis, diagnosis and exploration of SSc.
|
140 |
All |
18 Years and older (Adult, Senior) |
NCT02298777 |
5723 |
SCLEROMICS |
December 2014 |
December 2019 |
December 2019 |
November 24, 2014 |
September 8, 2017 |
|
- CHU
Dijon, France - CHU
Nancy, France - CHU
Reims, France
|
| 14 |
NCT03214263 |
Recruiting |
Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases |
- Arthritis, Rheumatoid
- Psoriatic Arthritis
- Axial Spondyloarthritis
- (and 2 more...)
|
|
Observational |
|
- Rigshospitalet, Denmark
- University Hospital, Gentofte, Copenhagen
- Copenhagen University Hospital at Herlev
- (and 10 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To diagnose inflammatory rheumatic diseases early in the disease course with high specificity and sensitivity
- To improve prognostication
- To predict treatment effectiveness and tolerability for the individual patient
|
20000 |
All |
18 Years and older (Adult, Senior) |
NCT03214263 |
REUM BIOMARKØRER 2014-10-30 |
|
May 2015 |
December 2024 |
December 2024 |
July 11, 2017 |
July 11, 2017 |
|
- Department of Rheumatology, Aalborg University Hospital
Aalborg, Denmark - Department of Rheumatology, Aarhus University Hospital
Aarhus, Denmark - Department of Rheumatology, Rigshospitalet
Copenhagen, Denmark - (and 8 more...)
|
| 15 |
NCT03029091 |
Recruiting |
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) |
|
|
Interventional |
Phase 2 |
- Children's Hospital Medical Center, Cincinnati
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Allergy and Infectious Diseases (NIAID)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Peak Esophageal Eosinophil Count
- Change in TGF-beta levels
|
15 |
All |
5 Years to 25 Years (Child, Adult) |
NCT03029091 |
2015-9021 |
|
January 19, 2017 |
September 2018 |
August 2019 |
January 24, 2017 |
January 24, 2017 |
|
- University of California, San Diego
La Jolla, California, United States - Northwestern University
Chicago, Illinois, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 16 |
NCT03490708 |
Not yet recruiting
New |
A Clinical Study of Tranilast in the Treatment of Mucinoses |
|
|
Interventional |
Early Phase 1 |
- The First Affiliated Hospital with Nanjing Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Measure the volume change of skin lesions by ultrasound
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT03490708 |
Mucinoses MH Hou |
|
April 2018 |
June 2022 |
December 2022 |
April 6, 2018 |
April 6, 2018 |
|
|
| 17 |
NCT01852851 |
Recruiting |
Employment and Arthritis: Making it Work |
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Lupus Erythematosus, Systemic
- (and 3 more...)
|
- Behavioral: Employment and Arthritis: Making it Work
|
Interventional |
Not Applicable |
- University of British Columbia
- Canadian Institutes of Health Research (CIHR)
- University of Toronto
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Efficacy analysis of at work productivity
- Efficacy analysis of work cessation
- Cost effectiveness analysis of at work productivity
- (and 7 more...)
|
526 |
All |
18 Years to 59 Years (Adult) |
NCT01852851 |
H11-03527 |
MIW |
June 2013 |
June 2020 |
June 2023 |
May 14, 2013 |
February 5, 2015 |
|
- Arthritis Research Centre
Richmond, British Columbia, Canada
|
| 18 |
NCT03430388 |
Recruiting |
Yellow Fever Vaccine in Patients With Rheumatic Diseases |
- Systemic Lupus
- Rheumatoid Arthritis
- Spondyloarthritis
- (and 8 more...)
|
- Biological: Yellow Fever vaccine (17D)
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of participants with severe adverse events to the fractional dose of Yellow Fever vaccine
- Number of participants with protective levels of antibodies against Yellow Fever vaccine
- Association of number of patients with protective antibodies levels and disease activity in patients with chronic rheumatic diseases
- Number of participants with persistent protective levels of antibodies against Yellow Fever
|
600 |
All |
2 Years to 60 Years (Child, Adult) |
NCT03430388 |
VFAReumatoHC |
|
January 31, 2018 |
March 24, 2018 |
February 24, 2019 |
February 12, 2018 |
April 9, 2018 |
|
- Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, Sao Paulo, Brazil
|
| 19 |
NCT03337165 |
Recruiting |
Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis |
- Musculoskeletal Diseases
- Joint Disease
- Arthritis
- (and 5 more...)
|
- Biological: tolerogenic dendritic cells
|
Interventional |
Phase 1 |
- Russian Academy of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants experiencing AEs and SAEs following the intra-articular administration of tDCs.
- Number of Participants Who Rated the Study and its Components as Partly or Completely Acceptable.
- Change from Baseline in DAS28 Score.
- Change from Baseline in the Health Assessment Questionnaire (HAQ)
|
15 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03337165 |
IFCI-14/10/2016 |
TolDCfoRA |
December 2016 |
March 2018 |
September 2018 |
November 8, 2017 |
November 8, 2017 |
|
- Institute of Fundamental and Clinical Immunology
Novosibirsk, Russian Federation
|
| 20 |
NCT02682511 |
Recruiting |
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension |
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Scleroderma, Limited
- (and 5 more...)
|
- Drug: Oral Ifetroban
- Drug: Oral Placebo
|
Interventional |
Phase 2 |
- Cumberland Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of adverse events (AEs) and Serious AEs (SAEs)
- Change from baseline in forced vital capacity (FVC)
- Change from baseline in diffusion capacity for carbon monoxide (DLCO)
- Change from baseline in the modified Rodnan skin score (mRSS)
|
34 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02682511 |
CPI-IFE-004 |
|
January 2017 |
December 2018 |
December 2019 |
February 15, 2016 |
January 5, 2018 |
|
- UCLA
Los Angeles, California, United States - Johns Hopkins University
Baltimore, Maryland, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 3 more...)
|
| 21 |
NCT03388255 |
Recruiting |
Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases |
|
- Drug: Polydeoxyribonucleotides
|
Interventional |
Phase 4 |
- Mastelli S.r.l
- Sintesi Research Srl
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Localized Scleroderma Cutaneous Assessment Tool - LOSCAT
- tele-thermographic profile
- ultrasound profile
- (and 2 more...)
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT03388255 |
PDRN-01-16 |
|
November 8, 2016 |
March 8, 2018 |
September 8, 2018 |
January 2, 2018 |
January 3, 2018 |
|
- IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
|
| 22 |
NCT03351114 |
Not yet recruiting |
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in dermal thickness of sentinel plaque
- Change in DIET score of sentinel plaque
- Change in LoSCAT score
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03351114 |
Pro00086947 |
|
January 2018 |
June 2019 |
June 2019 |
November 22, 2017 |
November 22, 2017 |
|
|
| 23 |
NCT03262922 |
Recruiting |
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment |
|
|
Observational |
|
- Rennes University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Questionnaire to evaluate the exposition of environmental and professional toxics
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT03262922 |
35RC16_3032_PRESSY |
PRESSY |
July 29, 2016 |
December 31, 2020 |
July 2021 |
August 25, 2017 |
August 25, 2017 |
|
- CHU de Rennes
Rennes, France
|
| 24 |
NCT03219606 |
Recruiting |
Impact of Education and Training of Modified Rodnan Skin Scoring on the Reliability of Test |
|
- Other: Organized education course of Modified Rodnan Skin Scoring
|
Interventional |
Not Applicable |
- Seoul National University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in difference between score measured by each participant and standard score after the organized education course.
- Change in written test score of each participant after the organized education course
- Change in inter-observer reliability of MRSS after the organized education course
|
10 |
All |
Child, Adult, Senior |
NCT03219606 |
1715-133-856 |
|
June 19, 2017 |
October 31, 2017 |
June 30, 2018 |
July 17, 2017 |
July 17, 2017 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
| 25 |
NCT03122431 |
Recruiting |
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases |
- Systemic Lupus Erythematosus (SLE)
- Juvenile SLE
- Cutaneous Lupus
|
- Drug: Thalidomide
- Drug: Hydroxychloroquine reduced
- Drug: Hydroxychloroquine high
|
Interventional |
Phase 4 |
- University of Sao Paulo General Hospital
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum levels of thalidomide
- Serum levels of hydroxycloroquine - HCQ reduced
- Serum levels of hydroxycloroquine - HCQ high
|
296 |
All |
5 Years to 64 Years (Child, Adult) |
NCT03122431 |
HPLC-Rheumatic diseases |
|
June 5, 2017 |
June 1, 2020 |
June 5, 2022 |
April 20, 2017 |
April 19, 2018 |
|
- Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, Brazil
|
| 26 |
NCT02887495 |
Recruiting |
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma) |
|
|
Observational |
|
- George Washington University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Modified Rodnan Skin Score
- Medsger Severity Score
|
600 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02887495 |
051427 |
|
July 2014 |
July 2024 |
|
September 2, 2016 |
December 20, 2017 |
|
- Victoria K Shanmugam
Washington, District of Columbia, United States
|
| 27 |
NCT02866552 |
Not yet recruiting |
SCLERoderma et Adipose-DErived Stroma Cells |
|
- Drug: Stromal Vascular fraction
- Drug: Ringer lactate
|
Interventional |
Phase 2 |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Cochin hand functional scale
- the severity (frequency and intensity of crises) of Raynaud's phenomenon
- the strength (Jamar et Pinch test)
- (and 2 more...)
|
44 |
All |
18 Years and older (Adult, Senior) |
NCT02866552 |
2016-40 |
SCLERADECIII |
January 2017 |
January 2019 |
August 2019 |
August 15, 2016 |
August 15, 2016 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
| 28 |
NCT02851875 |
Recruiting |
Duke Scleroderma Clinic Patient Registry |
- Scleroderma
- Systemic Sclerosis
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in disease activity as measured by Rodnan Skin Score
- Change in disease activity as measured by patient reported Scleroderma Health Associated Questionnaire (SHAQ)
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT02851875 |
Pro00067280 |
|
April 2016 |
December 2026 |
December 2026 |
August 2, 2016 |
May 2, 2017 |
|
- Duke University
Durham, North Carolina, United States
|
| 29 |
NCT02525835 |
Not yet recruiting |
Tissue Sodium in Autoimmune Disease |
- Systemic Lupus Erythematosus
|
- Dietary Supplement: Low Dietary Sodium
- Dietary Supplement: High Dietary Sodium
|
Interventional |
Not Applicable |
- Vanderbilt University
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- sodium concentration in skin
- SLEDAI
- blood pressure
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT02525835 |
150713 |
|
December 1, 2018 |
August 2020 |
August 2020 |
August 17, 2015 |
January 25, 2018 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
| 30 |
NCT02370784 |
Recruiting |
Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma |
|
- Drug: atorvastatin
- Drug: Placebo
|
Interventional |
Phase 2 |
- Robyn T. Domsic, MD, MPH
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pittsburgh
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- effect of atorvastatin therapy on change in microvascular endothelial function by Noninvasive vascular testing.
- effect of atorvastatin on change in Raynaud symptoms measured by a patient reported questionnaire.
- effect of atorvastatin on change in microcirculatory flow by Noninvasive vascular testing.
- effect of atorvastatin on change in macrovascular endothelial function by using Noninvasive vascular testing.
|
30 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02370784 |
PRO14010170
1R21AR066305-01A1 |
TAMER |
February 2015 |
February 2019 |
December 2019 |
February 25, 2015 |
March 15, 2018 |
|
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
| 31 |
NCT02213705 |
Recruiting |
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells |
- SYSTEMIC SCLERODERMA
- ALLOGENEIC MESENCHYMAL STEM CELLS
- ADULT
|
- Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
|
Interventional |
Phase 1
Phase 2 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- toxicity
- survival
- progression free survival
- (and 2 more...)
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02213705 |
MSC Severe Systemic Sclerosis |
MSC |
June 2014 |
June 2018 |
June 2019 |
August 11, 2014 |
April 18, 2016 |
|
- Saint-Louis Hospital
Paris, France
|
| 32 |
NCT03293719 |
Recruiting |
Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic |
- Osteoarthritis
- Osteoarthritis, Knee
- Joint Instability
- (and 4 more...)
|
- Device: BPK-S Integration UC
|
Observational |
|
- Peter Brehm GmbH
- P.R.I.S.M.A.-CRO
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Patient relevant benefit after 5 years
- Patient relevant benefit as measured by American Knee Society Score
- Patient relevant benefit as measured by Knee Osteoarthritis Outcome Score
- (and 5 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT03293719 |
2017-02-BPK-S Comparison |
|
March 20, 2018 |
December 1, 2024 |
April 1, 2025 |
September 26, 2017 |
March 26, 2018 |
|
- SMZ Ost, Donauspital
Vienna, Oberösterreich, Austria
|
| 33 |
NCT03262909 |
Recruiting |
Pivotal Study to Evaluate the Safety and Efficacy of GelrinC for Treatment of Cartilage Defects |
- Articular Cartilage Defects in the Knee Joint
|
- Device: GelrinC
- Other: Microfracture historical control arm
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change of physical functioning as assessed by patient reported outcome measure (Knee injury and Osteoarthritis Outcome Score (KOOS).
- The change of physical pain as assessed by patient reported outcome measure (Knee injury and Osteoarthritis Outcome Score (KOOS).
|
181 |
All |
18 Years to 50 Years (Adult) |
NCT03262909 |
CLN-GR-01 |
SAGE |
November 14, 2017 |
April 2021 |
November 2023 |
August 25, 2017 |
April 11, 2018 |
|
- Peninsula Orthopaedic Associates
Salisbury, Maryland, United States
|
| 34 |
NCT01808937 |
Recruiting |
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository |
- Scleroderma, Localized
- Morphea
- Frontal Linear Scleroderma en Coup de Sabre
- (and 2 more...)
|
|
Observational |
|
- University of Texas Southwestern Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Activity/damage measurement in morphea as scored on the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT)
- Quality of life scores measured by the Dermatology Life Quality Index (DLQI)
|
500 |
All |
up to 90 Years (Child, Adult, Senior) |
NCT01808937 |
032007021 |
MAC |
May 2007 |
January 2020 |
|
March 11, 2013 |
December 4, 2014 |
|
- UT Southwestern Medical Center - Department of Dermatology
Dallas, Texas, United States
|
| 35 |
NCT01776190 |
Recruiting |
Low-dose UVA1 Radiation in Cutaneous Lupus Patients |
- Cutaneous Lupus Erythematosus
|
- Device: UVA1 radiation treatment
|
Interventional |
Not Applicable |
- Ben Chong
- Daavlin Corporation
- University of Texas Southwestern Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CLASI activity score
- Lupus flares
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT01776190 |
072012-024 |
|
September 2012 |
September 2020 |
September 2020 |
January 28, 2013 |
October 26, 2017 |
|
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
|
| 36 |
NCT03101163 |
Recruiting |
Efficacy and Safety Study of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee |
- Articular Cartilage Disorder of Knee
- Articular Cartilage; Degeneration
|
- Biological: Autologous peripheral blood stem cells and hyaluronic acid
- Other: Hyaluronic acid
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- International Knee Documentation Committee (IKDC) score
- Knee injury and Osteoarthritis Outcome (KOOS) pain subdomain
- Numeric Rating Scale (NRS) for pain
|
120 |
All |
18 Years to 55 Years (Adult) |
NCT03101163 |
KLSMC-003 |
|
December 2015 |
September 2019 |
September 2021 |
April 4, 2017 |
April 4, 2017 |
|
- Andrews Research & Education Foundation (AREF)
Gulf Breeze, Florida, United States - Kuala Lumpur Sports Medicine Centre
Kuala Lumpur, Malaysia
|
| 37 |
NCT03024307 |
Recruiting |
The Effect of OPCSP on Adherence and Clinical Outcomes Among Patients With Rheumatic Diseases |
|
- Other: pharmacists involved OPCSP
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Medication adherence in the OPCSP program compared with usual care
- Changes in medical outcomes from baseline at each visit by EQ5D-3L
- changes in direct costs from baseline at each visit
|
600 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03024307 |
OPCSP2016 |
|
January 18, 2017 |
August 2018 |
October 2018 |
January 18, 2017 |
January 24, 2017 |
|
- South Campus, Ren Ji Hospital
Shanghai, China
|
| 38 |
NCT02991300 |
Recruiting |
BioPoly® RS Partial Resurfacing Patella Registry Study |
|
- Device: BioPoly RS Partial Resurfacing Patella Implant
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
|
- KOOS Subscores
- Kujala Anterior Knee Pain Scale
- Medical Outcomes Study (SF-36) for generic "quality of life"
- (and 3 more...)
|
35 |
All |
21 Years and older (Adult, Senior) |
NCT02991300 |
1251001 V2.0 |
|
September 2016 |
December 2022 |
|
December 13, 2016 |
December 13, 2016 |
|
- The London Clinic
London, England, United Kingdom
|
| 39 |
NCT01656447 |
Recruiting |
Scleroderma Registry & Repository at the Hospital for Special Surgery |
|
|
Observational |
|
- Hospital for Special Surgery, New York
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Modified Rodnan Skin Score
- Scleroderma Health Assessment Questionnaire
- Short Form-36
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT01656447 |
2014-276 |
|
August 2006 |
January 2030 |
|
August 3, 2012 |
March 15, 2018 |
|
- Hospital for Special Surgery
New York, New York, United States
|
| 40 |
NCT02941120 |
Recruiting |
Non-interventional Study With NOVOCART® Inject in the Reconstruction of the Knee Cartilage Defects |
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Number of adverse drug reaction/serious adverse drug reaction
- Outcome of IKDC 2000
- Outcome of KOOS
|
125 |
All |
14 Years to 50 Years (Child, Adult) |
NCT02941120 |
AAG-O-H-1521 |
RENOVO |
December 2015 |
July 2017 |
September 2017 |
October 21, 2016 |
June 26, 2017 |
|
- Hochtaunus-Kliniken gGmbH Krankenhaus Bad Homburg
Bad Homburg, Germany - Gelenk-Klinik Gundelfingen
Gundelfingen, Germany - Orthopädische Praxisklinik im Zentrum
Kelkheim, Germany - (and 6 more...)
|
| 41 |
NCT02659215 |
Recruiting |
HyaloFAST Trial for Repair of Articular Cartilage in the Knee |
- Defect of Articular Cartilage
|
- Device: Hyalofast
- Procedure: Microfracture
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Superiority of Hyalofast with Bone Marrow Aspirate Concentrate (BMAC) vs. Microfracture for % Change in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain Score
- Superiority of Hyalofast with Bone Marrow Aspirate Concentrate (BMAC) vs. Microfracture for % Change in International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score
- Superiority of Hyalofast® with autologous BMAC vs. Microfracture for change in MRI MOCART Score from baseline to two years post-surgery
- (and 4 more...)
|
200 |
All |
18 Years to 60 Years (Adult) |
NCT02659215 |
Hyalofast 15-01 |
FastTRACK |
December 2015 |
December 2020 |
December 2021 |
January 20, 2016 |
January 17, 2018 |
|
- Physicians Research Group
Tempe, Arizona, United States - Orthopedic Foundation
Stamford, Connecticut, United States - OrthoIllinois
Rockford, Illinois, United States - (and 24 more...)
|
| 42 |
NCT01413100 |
Recruiting |
Scleroderma Treatment With Autologous Transplant (STAT) Study |
|
- Biological: Anti-Thymocyte Globulin
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- (and 7 more...)
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- EFS of patients undergoing chemotherapy and transplant
- All-cause mortality
- Change in cardiac function
- (and 16 more...)
|
30 |
All |
up to 70 Years (Child, Adult, Senior) |
NCT01413100 |
2533.00
NCI-2011-01190
2533
P30CA015704 |
STAT |
September 15, 2011 |
September 1, 2019 |
|
August 10, 2011 |
January 9, 2018 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado
Denver, Colorado, United States - (and 13 more...)
|
| 43 |
NCT02418442 |
Recruiting |
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry |
|
|
Observational |
|
- Duke University
- Childhood Arthritis and Rheumatology Research Alliance
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prospectively collect essential data elements from children, adolescents and young adults with pediatric rheumatic diseases
- Evaluate the safety of therapeutic agents in persons with pediatric onset rheumatic diseases
- Evaluate clinical outcomes associated with the use of therapeutic agents in persons with pediatric onset rheumatic diseases
- (and 2 more...)
|
10000 |
All |
2 Years to 21 Years (Child, Adult) |
NCT02418442 |
Pro00054616 |
|
July 2015 |
June 2028 |
December 2028 |
April 16, 2015 |
February 19, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Mattel Children's Hospital at University of California Los Angeles
Los Angeles, California, United States - Stanford University Medical Center
Palo Alto, California, United States - (and 60 more...)
|
| 44 |
NCT00074568 |
Recruiting |
Scleroderma Registry |
- Systemic Sclerosis
- Scleroderma
|
|
Observational |
|
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- The University of Texas Health Science Center, Houston
|
NIH / Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Establish National registry of Scleroderma as resource for scleroderma scientific community
|
5000 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00074568 |
NIAMS-108
N01AR02251-000
NO1-AR-0-2251 |
Registry |
September 2000 |
January 2022 |
|
December 17, 2003 |
January 6, 2016 |
|
- University of Texas - Houston Medical School
Houston, Texas, United States
|
| 45 |
NCT00024479 |
Recruiting |
Natural History of Rheumatic Diseases in Minority Communities |
|
|
Observational |
|
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To generate hypotheses relating to basis and/or effects of health disparities in the community, which may serve as basis for subsequent research efforts based in the community and/or at NIH Clinical Center.
|
100000 |
All |
18 Years and older (Adult, Senior) |
NCT00024479 |
010227
01-AR-0227 |
|
September 12, 2001 |
|
|
September 14, 2001 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 46 |
NCT01729455 |
Recruiting |
Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry |
- Systemic Lupus Erythematosus
|
- Biological: BENLYSTA
- Other: SLE treatment
|
Observational |
|
- Human Genome Sciences Inc., a GSK Company
- GlaxoSmithKline
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of adverse events of special interest
- Change in organ damage
- Change in concomitant SLE medication use
- (and 5 more...)
|
3000 |
All |
18 Years and older (Adult, Senior) |
NCT01729455 |
116543
HGS1006-C1124 |
SABLE |
February 21, 2013 |
January 31, 2025 |
January 31, 2025 |
November 20, 2012 |
February 28, 2018 |
|
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Glendale, Arizona, United States - GSK Investigational Site
Goodyear, Arizona, United States - (and 191 more...)
|
| 47 |
NCT03198689 |
Not yet recruiting |
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis |
- Diffuse Cutaneous Systemic Sclerosis
|
- Drug: Brentuximab Vedotin
|
Interventional |
Phase 2 |
- Lawson Health Research Institute
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in skin thickness measured by modified Rodnan Skin Score (mRSS)
- Change in mRSS
- CRISS score >20%
- (and 5 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03198689 |
BV201708 |
|
September 1, 2018 |
November 1, 2018 |
June 1, 2019 |
June 26, 2017 |
March 7, 2018 |
|
- Rheumatology Clinic, St. Joseph's Health Care
London, Ontario, Canada
|
| 48 |
NCT03492255 |
Recruiting
New |
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid |
- Systemic Lupus Erythematosus (SLE)
|
- Drug: Cyclophosphamide
- Drug: Methylprednisolone
- Drug: Prednisone
- Drug: Mycophenolate Mofetil
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Partial renal response
- Complete renal response
- Osteoporosis evaluation
- (and 10 more...)
|
232 |
All |
18 Years and older (Adult, Senior) |
NCT03492255 |
CYCLONES |
CYCLONES |
April 12, 2018 |
October 30, 2018 |
December 31, 2022 |
April 10, 2018 |
April 17, 2018 |
|
- Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, Sao Paulo, Brazil - Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, Brazil
|
| 49 |
NCT03451422 |
Recruiting |
Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus |
- Systemic Lupus Erythematosus
|
- Drug: AMG 592
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of participants with Treatment-emergent Adverse Events.
- SRI-4 (Systemic Lupus Erythematosus Responder Index) response in subjects with a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) score ≥ 6 at baseline.
- CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index score) activity score change from baseline at week 24 in subjects with a CLASI activity score ≥ 10 at baseline.
- (and 26 more...)
|
132 |
All |
18 Years to 60 Years (Adult) |
NCT03451422 |
20170103
2017-002564-40 |
|
April 10, 2018 |
June 25, 2021 |
January 4, 2022 |
March 1, 2018 |
April 20, 2018 |
|
- Research Site
Great Neck, New York, United States - Research Site
Duncansville, Pennsylvania, United States - Research Site
Lille cedex 01, France - (and 5 more...)
|
| 50 |
NCT03427151 |
Recruiting |
Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus |
- Lupus Erythematosus, Systemic
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of adverse events throughout the study
- Clinical laboratory test results at each visit during the treatment extension period
- Body weight measurements at each visit during the treatment period
- (and 8 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03427151 |
IPP-201101/006 |
IP-006 |
February 27, 2018 |
October 2018 |
October 2018 |
February 9, 2018 |
April 20, 2018 |
|
- WALLACE
Los Angeles, California, United States - East Bay Rheumatology Medical
San Leandro, California, United States - Arthritis and Rheumatic Disease Specialties
Aventura, Florida, United States - (and 11 more...)
|
Create an RSS feed from your search for:
Download the search results for: